Navigation Links
Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
Date:6/28/2010

ificant bleeding, which in TRITON-TIMI 38 was significantly higher with Effient when compared with clopidogrel."

As pointed out in the Clinical Alert, research has shown other factors beyond genetics can negatively impact response to clopidogrel in some ACS-PCI patients. These factors include diabetes status, heart attack severity, stent type and concomitant medications.

In TRITON-TIMI 38, Effient produced reductions in the primary composite endpoint of CV death, nonfatal heart attack or nonfatal stroke that were consistent with that observed in the overall UA/NSTEMI and STEMI populations.  In the UA/NSTEMI population, the rate of the primary composite endpoint was 10 percent in patients with diabetes treated with Effient versus 15 percent in patients with diabetes treated with clopidogrel.  In the STEMI population, the rate of the primary composite endpoint was 9 percent in patients with diabetes treated with Effient versus 13.6 percent in patients with diabetes treated with clopidogrel.  In TRITON-TIMI 38 patients with diabetes, the risk of non-CABG TIMI major or minor bleeding was 4.9 percent for Effient versus 4.5 percent for clopidogrel.  In STEMI patients, the risk of non-CABG TIMI major or minor bleeding was 4.8 percent for Effient versus 4.5 percent for clopidogrel.  In the overall population TRITON-TIMI 38, the rates of non-CABG TIMI major or minor bleeding were 4.9 percent for prasugrel and 3.4 percent for clopidogrel (p=0.002).  

In TRITON-TIMI 38, there were 50 percent fewer stent thromboses (p<0.001) reported among patients randomized to Effient (0.9 percent) than among patients randomized to clopidogrel (1.8 percent).  The differences manifested early and were maintained though one year of follow-up, and findings were similar with bare metal and drug-eluting stents.

Finally, Effient can b
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
2. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
3. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
4. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
5. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
8. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
9. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
10. Coalition for Pulmonary Fibrosis Responds to News of Further Review of Pirfenidone By FDA
11. New Science Education Program Responds to Presidents Call to Help Young People Excel in Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... Pa. , Jan. 14, 2014 Dynamic Healthcare Services, ... announced today that it acquired Progressive Home Medical Equipment, Inc. ... 7, 2014. The terms of the acquisition were not disclosed. ... equipment ("DME") company providing a wide range of sleep, mobility, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 8, 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... that they have initiated the first of two Phase ... VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent ... treatment of Diabetic Macular Edema (DME).  The companies are ...
... (NASDAQ: IDIX ), a biopharmaceutical company engaged in ... human viral diseases, today announced that it has commenced an ... All of these shares are being sold by Idenix. ... book-running manager and underwriter for the offering. Idenix intends to ...
Cached Medicine Technology:Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 2Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 3Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 4Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 5Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 6Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock 2
(Date:4/18/2014)... (April 21, 2014) -- A group of scientists ... and the Sanders-Brown Center on Aging has found ... and neuropsychological function in Parkinson,s disease (PD). ... , the study, which assessed cognitive function in ... the dopamine replacement therapy commonly used to treat ...
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2
... Hopkins and elsewhere report what is believed to be ... inflammation of heart tissue and the subsequent damage leading ... latest findings from the Multiethnic Study of Atherosclerosis (MESA), ... the Journal of the American College of Cardiology, appear ...
... at Mattel Children,s Hospital UCLA have found that low-dose antidepressant ... adolescents suffering from irritable bowel syndrome, or IBS. ... students and 14 percent of high school kids in the ... the May issue of the peer-reviewed Journal of Pediatrics, is ...
... WASHINGTON, May 1 Speaker Nancy Pelosi today,released ... Information,Nondiscrimination Act, which the House passed this afternoon ... bill, which would prohibit health,insurance companies and employers ... test results, now goes to the President,s desk ...
... said today that there are more than 36,000 uninsured ... whom are on a waiting,list to receive health care ... a plan to help them gain access to health ... live with the,very real fear that a sudden illness ...
... Courage Center has received a,one-year grant of $150,000 ... to,support The Bridge to Independence. This coordinated campaign ... children with disabilities,through effective grassroots community organizing, policy ... leading member of the Minnesota Consortium of Citizens ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... present key scientific data on its Attention Deficit ... system and the investigational non-stimulant treatment under FDA ... Association (APA) annual meeting to be held May ...
Cached Medicine News:Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Antidepressant found to alleviate symptoms of irritable bowel syndrome in adolescents 2Health News:Pelosi: 'Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information' 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 3Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 4Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 5Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 6Health News:Courage Center Receives $150,000 Grant From Minneapolis Foundation 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: